xCellSense® produces functional drug-response data from primary patient samples — combination synergy, responder segmentation, and ML-based analytics — so you can decide go/no-go, dosing, and patient selection before the clinic.
Request a Quote
Roughly 90% of oncology candidates fail in the clinic — largely because animal and cell-line models don't predict efficacy. Genomics shows what is present, not what works. xCellSense® tests your asset in live primary cells from blood-cancer patients — the biology those models miss.
This is functional precision medicine aligned with where regulation is heading: the FDA Modernization Act 2.0 (2022) and the FDA's 2025 NAMs Roadmap make human-derived, cell-based functional data not just desirable, but expected.
xCellSense® processes a single primary patient sample using an integrated workflow:
Dose-response (IC₅₀, AUC, Eₘₐₓ) for your asset and comparators in the same patient cells — preserved in our proprietary Optimum Media, which maintains primary blood-cancer cell viability where conventional media fail.
Quantitative synergy and antagonism scoring (Bliss, Loewe, ZIP, HSA) to rank regimens — including the sponsor asset ± standard-of-care (SoC) backbones.
Population-resolved response, antigen density, and target engagement — measured in the malignant population, not the bulk well.
Machine-learning-driven analytics that score synergy, stratify responders from non-responders, and translate complex readouts into a sponsor-ready interpretation — not a raw-data dump.
ML-integrated synergy scoring on live, primary patient cells. Functional, human-relevant evidence — fast.
Commodity assays on slow timelines — no analytics layer, no hematology focus.
Propagated models at higher cost and longer timelines, a step removed from the patient.
Describe biology without predicting functional, disease-relevant drug response.
Delivery is governed by defined service-level commitments and quality infrastructure across two accredited labs, with audit-ready documentation throughout.
Services are for Research Use Only (RUO).
SILICON VALLEY
A2LA / ISO 17025
CLIA Certification in Progress
Accredited testing laboratory
SEOUL
KGMP / IVD-certified
Audit-ready quality documentation
Sponsor-ready report from a sample receipt — interpretation, figures, and dataset
Quantitative synergy matrices (Bliss / Loewe / ZIP / HSA) with combination ranking
Responder vs. non-responder segmentation to refine enrichment and inclusion criteria
Integrated functional + flow cytometry + optional NGS for genotype-to-phenotype-to-response correlation
Human-relevant NAM data to strengthen IND-stage and development packages (RUO)
Accredited labs (ISO 17025 / A2LA and KGMP) with audit-ready QC documentation
A scientist will scope a tailored study and return a design and timeline.
